Clinical trial results:
A Phase 1, open-label study to characterize the absorption, metabolism, and excretion of 14C-JNJ-53718678 after a single oral dose in healthy adult male subjects

Summary

EudraCT number	2016-002664-14
Trial protocol	
Global end of trial date	20 March 2017

Results information

Result version number	v1 (current)
This version publication date	
First version publication date	

Trial information

Trial identification

Sponsor protocol code	53718678RSV1008

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03002779
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Janssen-Cilag International NV
Sponsor organisation address	Archimedesweg 29, Leiden, Netherlands, 2333 CM
Public contact	Clinical Registry Group, Janssen-Cilag International NV, +31 71524 21 66, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen-Cilag International NV, +31 71524 21 66, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 March 2017
Is this the analysis of the primary	No

completion data?	
Global end of trial reached?	Yes
Global end of trial date	20 March 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the study was to determine the routes of excretion for JNJ-53718678 and its metabolites after administration of a single oral dose of 14C-JNJ-53718678; to explore the metabolic pathways of JNJ-53718678 after administration of a single oral dose of 14C-JNJ-53718678, and also to determine the chemical structure of predominant metabolites after administration of a single oral dose of 14C-JNJ-53718678 in healthy adult male subjects.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. The safety assessments included physical examination (including height and body weight measurement and skin examination), medical history, vital signs (systolic and diastolic blood pressure, pulse rate, orthostatic blood pressure changes, respiratory rate, and body temperature), clinical laboratory tests and electrocardiogram.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 January 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 6
Worldwide total number of subjects	6
EEA total number of subjects	6

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	6
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted in 1 center from 31 January 2017 to 20 March 2017.

Pre-assignment

Screening details:

A total of 6 subjects were enrolled and completed this study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	JNJ-53718678 500 mg

Arm description:

Subjects received a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678.

Arm type	Experimental
Investigational medicinal product name	JNJ-53718678
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects received a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678.

Number of subjects in period 1	JNJ-53718678 500 mg		
Started	6		
Completed	6		

Baseline characteristics

Reporting groups	
Reporting group title	JNJ-53718678 500 mg
Reporting group description:	
Subjects received a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678.	

Reporting group values	JNJ-53718678 500 mg	Total	
Number of subjects	6	6	
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	6	6	
From 65 to 84 years	0	0	
85 years and over	0	0	
Title for AgeContinuous Units: years			
arithmetic mean	28.5		
standard deviation	± 6.89	-	
Title for Gender Units: subjects			
Male	6	6	

End points

End points reporting groups

Reporting group title	JNJ-53718678 500 mg

Reporting group description:

Subjects received a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678.

Primary: Mass Balance: Amount of Total Radioactivity Recovered in Urine and Feces

End point title	Mass Balance: Amount of Total Radioactivity Recovered in Urine and Feces[1]

End point description:

Percentage of dose recovered in urine and feces was reported. PK analysis set included all subjects who were enrolled in the study and received the study drug.

End point type	Primary

End point timeframe:

0-144 hours post dose (approximately up to Day 10)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	JNJ-53718678 500 mg			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Percentage of dose recovered				
arithmetic mean (standard deviation)				
Urine	19.9 (± 1.74)			
Feces	70.6 (± 2.90)			
Total	90.5 (± 1.88)			

Statistical analyses

No statistical analyses for this end point

Primary: Ratio of Area Under Plasme Concentration Time curve from time 0 to Infinity (AUC∞) of JNJ-53718678 and of Total Radioactivity (TR) in Plasma

End point title	Ratio of Area Under Plasme Concentration Time curve from time 0 to Infinity (AUC∞) of JNJ-53718678 and of Total Radioactivity (TR) in Plasma[2]

End point description:

The AUC∞ is the area under the plasma concentration-time curve from time zero to infinity. Ratio of AUC∞ of JNJ-53718678 (parent drug) and of TR in plasma was reported.

End point type	Primary

End point timeframe:

2 hour (h) predose; 1, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 h post dose on Day 1; 24 and 36 h post dose on Day 2, 48 h post dose on Day 3, 72 h post dose on Day 4, 96 h post dose on Day 5, and 120 h post dose on Day 6

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	JNJ-53718678 500 mg			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Ratio				
arithmetic mean (standard deviation)	47.39 (± 2.31)			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Dose Excreted in Urine as Unchanged JNJ-53718678

End point title	Percentage of Dose Excreted in Urine as Unchanged JNJ-53718678[3]

End point description:

The amount of unchanged drug excreted in urine, expressed as percentage of dose.

End point type	Primary

End point timeframe:

Up to day 10

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	JNJ-53718678 500 mg			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Percentage of dose				
arithmetic mean (standard deviation)	1.56 (± 0.334)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Treatment-Emergent Adverse Events

End point title	Number of Subjects with Treatment-Emergent Adverse Events

End point description:

An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Safety analysis set included all subjects who were enrolled in the study and received study drug.

End point type	Secondary

End point timeframe:

Up to Day 16

End point values	JNJ-53718678 500 mg			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Number of subjects	6			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
From Baseline up to 16 days	
Assessment type	Non-systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	19.0
Reporting groups	
Reporting group title	JNJ-53718678 500 mg
Reporting group description:	
Subjects received a single 500 mg dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678.	

Serious adverse events	JNJ-53718678 500 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	JNJ-53718678 500 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 6 (66.67%)		
Eye disorders			
Eye Irritation			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Toothache			

subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Musculoskeletal and connective tissue disorders Myalgia subjects affected / exposed occurrences (all)	 1 / 6 (16.67%) 1		
Infections and infestations Rhinitis subjects affected / exposed occurrences (all)	 1 / 6 (16.67%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported